We present the cloning and characterization of two novel calcium-activated potassium channel ␤ subunits, hKCNMB3 and hKCNMB4, that are enriched in the testis and brain, respectively. We compare and contrast the steady state and kinetic properties of these ␤ subunits with the previously cloned mouse ␤1 (mKCNMB1) and the human ␤2 subunit (hKCNMB2). Once inactivation is removed, we find that hKCNMB2 has properties similar to mKCNMB1. hKCNMB2 slows Hslo1 channel gating and shifts the current-voltage relationship to more negative potentials. hKCNMB3 and hKCNMB4 have distinct effects on slo currents not observed with mKCNMB1 and hKCNMB2. Although we found that hKCNMB3 does interact with Hslo channels, its effects on Hslo1 channel properties were slight, increasing Hslo1 activation rates. In contrast, hKCNMB4 slows Hslo1 gating kinetics, and modulates the apparent calcium sensitivity of Hslo1. We found that the different effects of the ␤ subunits on some Hslo1 channel properties are calcium-dependent. mKCNMB1 and hKCNMB2 slow activation at 1 M but not at 10 M free calcium concentrations. hKC-NMB4 decreases Hslo1 channel openings at low calcium concentrations but increases channel openings at high calcium concentrations. These results suggest that ␤ subunits in diverse tissue types fine-tune slo channel properties to the needs of a particular cell.The large conductance calcium-activated potassium channel (BK) 1 is a unique member of the six transmembrane domain potassium channel family that is activated by voltage and calcium. BK channels are composed of a pore-forming ␣ subunit (1, 2) and, in some tissues, are tightly associated with an accessory ␤ subunit (3, 4). BK channels have diverse physiological properties with tissue-specific distribution. In neurons, BK channels are functionally colocalized with calcium channels (5, 6), shape action potential wave forms (7,8), and modulate neurotransmitter release (9, 10). In smooth muscle, BK channels regulate constriction in arteries (11), uterine contraction (12), and filtration rate in the kidney (13). Unlike other potassium channel families, BK channels can as yet only be attributed to a single gene, slowpoke (slo), that encodes the poreforming ␣ subunit of the channel. In light of the broad tissue localization and diverse functional properties, it is not surprising that a number of mechanisms have been identified that alter slo channel properties. These include alternative splicing of the slo RNA (14 -18), heteromeric assembly with other subunits (slak) (19), and modification by phosphorylation/dephosphorylation (20 -22) and oxidation/reduction (23).In addition, accessory ␤ subunits are a means of generating BK channel diversity. Coexpression of the ␤1 subunit in Xenopus oocytes increases the apparent calcium sensitivity, slows activation kinetics, and increases charybdotoxin binding affinity (24 -27). ␤1 subunit mRNA is enriched in smooth muscle (28) and can account for the apparent increased calcium sensitivity of BK channels in that tissue relative to skeletal muscl...

Retigabine [N-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid; D-23129] is a novel anticonvulsant, unrelated to currently available antiepileptic agents, with activity in a broad range of seizure models. In the present study, we sought to determine whether retigabine could enhance current through M-like currents in PC12 cells and KCNQ2/Q3 K(+) channels expressed in Chinese hamster ovary cells (CHO-KCNQ2/Q3). In differentiated PC12 cells, retigabine enhanced a linopirdine-sensitive current. The effect of retigabine was associated with a slowing of M-like tail current deactivation in these cells. Retigabine (0.1 to 10 microM) induced a potassium current and hyperpolarized CHO cells expressing KCNQ2/Q3 cells but not in wild-type cells. Retigabine-induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM). The mechanism by which retigabine enhanced KCNQ2/Q3 currents involved large, drug-induced, leftward shifts in the voltage dependence of channel activation (-33.1 +/- 2.6 mV, n = 4, by 10 microM retigabine). Retigabine shifted the voltage dependence of channel activation with an EC(50) value of 1.6 +/- 0.3 microM (slope factor was 1.2 +/- 0.1, n = 4 to 5 cells per concentration). Retigabine (0.1 to 10 microM) also slowed the rate of channel deactivation, predominantly by increasing the contribution of a slowly deactivating tail current component. Our findings identify KCNQ2/Q3 channels as a molecular target for retigabine and suggest that activation of KCNQ2/Q3 channels may be responsible for at least some of the anticonvulsant activity of this agent.

Background:The molecular basis for sodium channel inhibition by spider venom peptides is poorly understood. Results: Key toxin residues and structural features important for activity of huwentoxin-IV are identified. Conclusion: Toxin activity involves a hydrophobic protrusion surrounded by a ring of basic residues. Significance: New structure-function information may provide a foundation for the design of peptides with therapeutic potential.

Background and Purpose An increasing body of evidence suggests that the purinergic receptor P2X, ligand‐gated ion channel, 7 (P2X7) in the CNS may play a key role in neuropsychiatry, neurodegeneration and chronic pain. In this study, we characterized JNJ‐47965567, a centrally permeable, high‐affinity, selective P2X7 antagonist. Experimental Approach We have used a combination of in vitro assays (calcium flux, radioligand binding, electrophysiology, IL‐1β release) in both recombinant and native systems. Target engagement of JNJ‐47965567 was demonstrated by ex vivo receptor binding autoradiography and in vivo blockade of Bz‐ATP induced IL‐1β release in the rat brain. Finally, the efficacy of JNJ‐47965567 was tested in standard models of depression, mania and neuropathic pain. Key Results JNJ‐47965567 is potent high affinity (pKi 7.9 ± 0.07), selective human P2X7 antagonist, with no significant observed speciation. In native systems, the potency of the compound to attenuate IL‐1β release was 6.7 ± 0.07 (human blood), 7.5 ± 0.07 (human monocytes) and 7.1 ± 0.1 (rat microglia). JNJ‐47965567 exhibited target engagement in rat brain, with a brain EC50 of 78 ± 19 ng·mL−1 (P2X7 receptor autoradiography) and functional block of Bz‐ATP induced IL‐1β release. JNJ‐47965567 (30 mg·kg−1) attenuated amphetamine‐induced hyperactivity and exhibited modest, yet significant efficacy in the rat model of neuropathic pain. No efficacy was observed in forced swim test. Conclusion and Implications JNJ‐47965567 is centrally permeable, high affinity P2X7 antagonist that can be used to probe the role of central P2X7 in rodent models of CNS pathophysiology.